We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission PR Newswire MIAMI, April 2, 2024 Ketamir-2 is a potential treatment...
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor PR Newswire MIAMI, March 21, 2024 A seasoned pharmaceutical industry...
MIRA Pharmaceuticals Provides Corporate Update PR Newswire BALTIMORE, Feb. 5, 2024 Announces Research Collaboration with Pharmaseed to Conduct Pre-Clinical Studies on the Use of Ketamir for...
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations PR Newswire BALTIMORE, Dec. 4, 2023 AI Simulation on MIRA1a Showcases Significant Potential Advantages...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0208 | 2.50602409639 | 0.83 | 0.9171 | 0.79 | 28336 | 0.8595749 | CS |
4 | -0.2492 | -22.6545454545 | 1.1 | 1.12 | 0.76 | 49984 | 0.95578906 | CS |
12 | -0.1117 | -11.6051948052 | 0.9625 | 1.84 | 0.76 | 725029 | 1.46585975 | CS |
26 | -1.3792 | -61.8475336323 | 2.23 | 6.4 | 0.76 | 460362 | 1.7956003 | CS |
52 | -6.1492 | -87.8457142857 | 7 | 7.9799 | 0.76 | 345603 | 2.11007386 | CS |
156 | -6.1492 | -87.8457142857 | 7 | 7.9799 | 0.76 | 345603 | 2.11007386 | CS |
260 | -6.1492 | -87.8457142857 | 7 | 7.9799 | 0.76 | 345603 | 2.11007386 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions